CPX

Drug Profile

CPX

Latest Information Update: 02 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA); Vanderbilt University
  • Developer SciClone Pharmaceuticals
  • Class Neuroprotectants; Small molecules; Xanthines
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 29 Mar 2001 CPX has received orphan drug status for cystic fibrosis in the European Union
  • 10 Nov 2000 CPX has been re-formulated for further phase II studies
  • 12 May 1999 Cystic Fibrosis Foundation awards SciClone $US517 000 research grant
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top